Herbal drugs an alternative medicine for the treatment of neurodegenerative diseases: Preclinical and clinical trial review

Shrivastava, Pallavi; Revoori, Anwita; Vaibhav, Kumar; Ahluwalia, Meenakshi; Saxena, Meghna

doi:10.1016/b978-0-323-90572-5.00031-7

Cited by 1 publication

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early diagnosis is essential for treatment planning and can help to optimize support for patients and their families in the long run [7]. Recent reviews have been published regarding the use of herbal medicine for the treatment of neurodegenerative diseases [8,9]. Therefore, herbal treatments should be considered a potential therapeutic candidate in order to tackle neurological disorders.…”

Section: Introductionmentioning

confidence: 99%

Neurological Applications of Celery (Apium graveolens): A Scoping Review

et al. 2023

View full text Add to dashboard Cite

Apium graveolens is an indigenous plant in the family Apiaceae, or Umbelliferae, that contains many active compounds. It has been used traditionally to treat arthritic conditions, gout, and urinary infections. The authors conducted a scoping review to assess the quality of available evidence on the overall effects of celery when treating neurological disorders. A systematic search was performed using predetermined keywords in selected electronic databases. The 26 articles included upon screening consisted of 19 in vivo studies, 1 published clinical trial, 4 in vitro studies and 2 studies comprising both in vivo and in vitro methods. A. graveolens and its bioactive phytoconstituent, 3-n-butylphthalide (NBP), have demonstrated their effect on neurological disorders such as Alzheimer’s disease, Parkinson’s disease, stroke-related neurological complications, depression, diabetes-related neurological complications, and epilepsy. The safety findings were minimal, showing that NBP is safe for up to 18 weeks at 15 mg/kg in animal studies, while there were adverse effects (7%) reported when consuming NBP for 24 weeks at 600 mg daily in human trials. In conclusion, the safety of A. graveolens extract and NBP can be further investigated clinically on different neurological disorders based on their potential role in different targeted pathways.

show abstract

Section: Introductionmentioning

confidence: 99%